Citations

AbstractBackgroundAn individualized, tissue‐engineered liver suitable for transplanting into a patient with liver disease would be of great benefit to the patient and the healthcare system. The tissue‐engineered liver would possess the functions of the original healthy organ. Two fields of study, (i) using decellularized tissue as cell scaffolding, and (ii) stem cell differentiation into functional cells, are coming together to make this concept feasible. The decellularized liver scaffolds (DLS) can interact with cells to promote cell differentiation and signal transduction and three‐dimensional (3D) stem cell aggregations can maintain the phenotypes and improve functions of stem cells after differentiation by undergoing cell‐cell contact. Although the effects of DLS and stem cell aggregation culture have been intensively studied, few observations about the interaction between the two have been achieved.MethodsWe established a method that combines the use of decellularized liver scaffolds and aggregation culture of MSCs (3D‐DLS) and explored the effects of the two on hepatic differentiation of human umbilical cord mesenchymal stem cells (hUC‐MSCs) in bioengineered hepatic tissue.ResultsA higher percentage of albumin‐producing cells, higher levels of liver‐specific transcripts, higher urea cycle‐related transcripts, and lower levels of stem cell‐specific transcripts were observed in the 3D‐DLS group when compared to that of hUC‐MSCs in monolayer culture (2D), aggregation culture (3D), monolayer on DLS culture (2D‐DLS). The gene arrays also indicated that 3D‐DLS induced the differentiation from the hUC‐MSC phenotype to the PHH phenotype. Liver‐specific proteins albumin, CK‐18, and glycogen storage were highly positive in the 3D‐DLS group. Albumin secretion and ammonia conversion to urea were more effective with a higher cell survival rate in the 3D‐DLS group for 14 days.ConclusionThis DLS and aggregation combination culture system provides a novel method to improve hepatic differentiation, maintain phenotype of hepatocyte‐like cells and sustain survival for 14 days in vitro. This is a promising strategy to use to construct bioengineered hepatic tissue.

The majority of cerebellopontine angle tumors are acoustic neurinomas; however, 10% to 15% are meningiomas. Meningiomas are benign lesions that must be removed but may require surgical approaches different from those used for acoustic neurinomas. To determine if meningiomas could be distinguished from acoustic neurinomas clinically, findings in 20 patients who underwent removal of a meningioma were compared to those in 131 patients who had an acoustic neurinoma removed during the same period. We found that in patients with meningiomas the tumors frequently are large at presentation, the otologic symptoms and audiometric findings are less dramatic, and roentgenograms of the skull and tomograms of the petrous apex rarely show erosion of the internal auditory canal. Computerized tomography is the most useful method for differentiating a meningioma from a neurinoma: when a meningioma is present the characteristic finding is a broad‐based mass aligned with the petrous ridge, not centered over the internal auditory canal.

In 1989, I reported a series of 19 cases of unilateral vocal cord paralysis treated by transcutaneous Teflon injection. At that time it was shown that unilateral vocal cord paralysis could be effectively treated in the office in the unanesthetized patient using a transcutaneous route of Injection. Since that time, an additional 43 patients have been treated using a similar technique. The initial impression of safety and efficacy has been confirmed in this subsequent series. Several refinements in this technique have simplified its use and improved its reliability. No airway complications have been observed to date and no patients have required hospital admission. Transcutaneous Teflon Injection can be considered a useful method for treatment of vocal cord paralysis in selected patients.